Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey
Authors:
- 2 December 2021
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (1S) , e837-e842
Abstract
Background Multiple investigations are available to aid the diagnosis and monitoring of disease activity in inflammatory bowel disease (IBD). Fecal calprotectin (FC) is an established surrogate for intestinal inflammatory activity. Therapeutic drug monitoring (TDM) including thiopurine metabolites, anti-tumor necrosis factor (TNF) levels and antidrug antibody measurements are a step toward personalized medicine in IBD, but face access barriers. We aimed to assess test availability and barriers for these investigations in European practice. Methods Five-hundred questionnaires were distributed to workshop participants at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO). Access to FC, TDM for thiopurines and anti-tumor necrosis factor agents, as well as factors associated with usage and barriers to access were recorded. Results Responses were obtained from 195 attendees from 38 countries across a range of practices, healthcare settings and levels of experience. FC was available to 92.3% while access to anti-TNF (78.9%, P = 0.02 vs. thiopurine TDM, P = 0.0002 vs. FC) and thiopurine TDM (67.7%, P = 0.0001) were less widespread. Cost was a frequently cited barrier to test access or usage, with access having a significant West–East and North–South divide across all three investigations. The strongest independent predictor of access to all tests was healthcare spending per capita (P = 0.005 for FC; P < 0.0001 for both TDM). Conclusion FC, anti-TNF and thiopurine TDM are increasingly incorporated as part of routine practice in IBD care across Europe and have the potential to impact positively on patient care. However, access barriers remain of which we found test cost the most significant with the investment required to reduce these barriers.Keywords
This publication has 20 references indexed in Scilit:
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetAmerican Journal of Gastroenterology, 2015
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel DiseaseGastroenterology, 2015
- Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After SurgeryGastroenterology, 2015
- Toxicity and response to thiopurines in patients with inflammatory bowel diseaseExpert Review of Gastroenterology & Hepatology, 2015
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled TrialAmerican Journal of Gastroenterology, 2014
- Effectiveness and Cost-effectiveness of Measuring Fecal Calprotectin in Diagnosis of Inflammatory Bowel Disease in Adults and ChildrenClinical Gastroenterology and Hepatology, 2014
- Tailoring anti-TNF therapy in IBD: drug levels and disease activityNature Reviews Gastroenterology & Hepatology, 2014
- East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohortGut, 2013
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective studyAlimentary Pharmacology & Therapeutics, 2011